Rockefeller Capital Management
CYTO

Rockefeller Capital Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Rockefeller Capital Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 4132
2021
Q4 		$0 Hold
1
– – ﹤0.01% 4048
2021
Q3 		$0 Hold
1
– – ﹤0.01% 3903
2021
Q2 		$0 Buy
+1
New +$1.37K ﹤0.01% 3653

Other funds holding CYTO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Rockefeller Capital Management's CYTO Position: Q1 2022 in Review

Rockefeller Capital Management sold out of Altamira Therapeutics Ltd (CYTO) in Q1 2022, closing a stake of 1 share.

Rockefeller Capital Management first reported a position in CYTO in Q2 2021 and held it in 3 quarters. The position peaked at $0 in Q4 2021. 14 funds tracked by Wall St. Rank hold CYTO as of Q1 2022.

  • Rockefeller Capital Management reported no remaining Altamira Therapeutics Ltd position as of Q1 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 1 Altamira Therapeutics Ltd share in Q1 2022.
  • Rockefeller Capital Management first reported a position in Altamira Therapeutics Ltd in Q2 2021 and held it in 3 quarters.
  • Rockefeller Capital Management's Altamira Therapeutics Ltd position peaked at $0 in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q1 2022.

Based on Rockefeller Capital Management's 13F filing for Q1 2022, filed 13 May 2022.